Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)’s stock price has decreased by -0.31 compared to its previous closing price of 0.16. However, the company has seen a 11.72% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-06 that Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Right Now?
Additionally, the 36-month beta value for TNXP is 2.12. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TNXP is 22.00M and currently, short sellers hold a 7.13% ratio of that float. The average trading volume of TNXP on September 13, 2024 was 19.98M shares.
TNXP’s Market Performance
TNXP stock saw a decrease of 11.72% in the past week, with a monthly decline of -68.44% and a quarterly a decrease of -85.39%. The volatility ratio for the week is 21.00%, and the volatility levels for the last 30 days are 23.11% for Tonix Pharmaceuticals Holding Corp (TNXP). The simple moving average for the last 20 days is -42.58% for TNXP stock, with a simple moving average of -97.59% for the last 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at -64.72% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.47% of loss for the given period.
Volatility was left at 23.11%, however, over the last 30 days, the volatility rate increased by 21.00%, as shares sank -65.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.14% lower at present.
During the last 5 trading sessions, TNXP rose by +12.07%, which changed the moving average for the period of 200-days by -98.98% in comparison to the 20-day moving average, which settled at $0.2624. In addition, Tonix Pharmaceuticals Holding Corp saw -98.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.64 for the present operating margin
- -0.0 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -11.96. The total capital return value is set at -1.97. Equity return is now at value -163.24, with -129.55 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -8.23. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -53.18.
Currently, EBITDA for the company is -114.09 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 0.69. The receivables turnover for the company is 3.73for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.15.
Conclusion
In conclusion, Tonix Pharmaceuticals Holding Corp (TNXP) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
